The test reported accuracy exceeding 80% in lung cancer detection. As well, the test could identify the subtype of lung cancer — small cell, adenocarcinoma or squamous cell — with accuracy approaching 90%.
These results show that the first generation of our breath test technology compares well with CT scans. Detection of the metabolomic signature of lung cancer in exhaled breath is non-invasive, rapid, and inexpensive, and will become a valuable adjunct to help assess an indeterminate CT, and may come to have a central role in early detection and differentiation of lung cancer, while lowering costs to the health-care system.
